SAMHSA Said Fentanyl Test Strips Save Lives. Nine Months Later It Banned Federal Funding for Them.

On July 29, 2025, the Substance Abuse and Mental Health Services Administration told every state and grantee, in a Dear Colleague letter, exactly what its money could still buy under a new executive order narrowing "harm reduction" funding.▸ Under "Life-Saving Overdose Prevention and Response Services," the letter listed naloxone, medication lock boxes — and "substance test kits, including fentanyl test strips and xylazine test strips." SAMHSA was explicit that the strips, which let a person check a drug supply for fentanyl before using it, belonged in the same life-saving category as the overdose-reversal drug itself.

Nine months later, the same office reversed itself.▸ An April 24, 2026 letter moved fentanyl and xylazine test strips — along with newly named medetomidine strips — into the list of supplies "NOT supported with SAMHSA funding," alongside syringes and safer-smoking pipes. Naloxone stayed funded. The strip a user reads before injecting did not.

Both letters trace to the same order: Executive Order 14321, "Ending Crime and Disorder on America's Streets," signed July 24, 2025, which directed HHS to "ensure that discretionary grants issued by [SAMHSA] for substance use disorder prevention, treatment, and recovery fund evidence-based programs and do not fund programs that fail to achieve adequate outcomes, including so-called 'harm reduction' ... efforts that only facilitate illegal drug use."▸ The July 2025 letter interpreted that order narrowly: fentanyl test strips survived because SAMHSA classified them as overdose prevention, not "harm reduction" in the sense the order targeted. The April 2026 letter, signed by the same office under a new principal deputy assistant secretary, redrew that line — this time putting test strips on the banned side, alongside sterile water and "overdose hotlines" that let someone stay on the phone while using. A footnote in the new letter carves out an exception: the ban on federal money buying test strips does not apply to "law enforcement, emergency medical services, public health officials, or healthcare professionals" using them in their own work. It applies to people who use drugs testing their own supply.

The backdrop makes the timing sharper.▸ CDC's own live data put U.S. overdose deaths at a model-adjusted 70,207 for the 12 months ending December 2025 — down from 81,313 a year earlier, and the third straight annual decline after a 2022 peak above 110,000. CDC's official May 2026 release rounded the final count to 69,973, a level the agency hadn't seen since before the pandemic. The July 2025 SAMHSA letter itself cited "CDC's latest provisional data" — a 26% year-over-year decline as of February 2025 — as the backdrop for its own harm-reduction policy, while still allowing test strips as one of the tools driving that decline. The April 2026 letter doesn't dispute the trend. It just moves the strip off the funded list anyway.

The executive order's broader target — federal support for syringe service programs (SSPs), which combine sterile syringes with naloxone, wound care, and referrals to treatment — is the subject of a June 2026 study in JAMA Network Open.▸ Researchers at the University of Colorado Anschutz Medical Campus built a microsimulation of the roughly 3,694,500 people who inject drugs nationally and modeled two funding-cut scenarios, drawn from published estimates of how much SSP money nationally traces to federal sources — 11% at the low end, 80% at the high end, since federal block-grant dollars often reach SSPs indirectly through state or local health departments. Under the study's worst case — an 80% sustained cut in federal support — the model projects 39,600 additional deaths over five years among people who inject drugs, 15,600 of them from overdose. Even the conservative 11% scenario projects 5,400 excess deaths, 2,200 from overdose.

Federal money is not, today, the majority of what keeps most syringe programs running.▸ In the most recent national census — 311 of 456 known U.S. SSPs surveyed in 2022, a 68% response rate — state health departments were the most commonly cited funding source, reported by 63% of programs, ahead of individual donations (42%) and private foundations (29%). The federal government, reported directly, was the least common source: 11%. The median SSP ran on a $100,000 annual budget — an amount the same study found covered as little as 5% of the minimum benchmark for rural counties and 46% for urban ones. That 11% floor is exactly the JAMA study's conservative scenario; the 80% ceiling belongs to programs, mostly rural and state-run, where federal block grants are effectively the whole budget once relabeled as "state" funding on a survey form.

The dollars that fund state substance-use systems, including the block grants SSPs draw on, moved through Congress largely intact.▸ The Consolidated Appropriations Act, 2026, approved by Congress February 3, 2026, provides $1.9 billion for the Substance Use Prevention, Treatment, and Recovery Services Block Grant — the main federal channel for state substance-use programs — alongside $1.6 billion for State Opioid Response grants and $1 billion for the Mental Health Block Grant. In January 2026, SAMHSA briefly moved to terminate roughly $2 billion in discretionary grants outright, then reversed the terminations within about 24 hours after bipartisan pushback. The money is still flowing. What changed is what grantees are allowed to buy with it — and the list of banned supplies got longer, not shorter, in the nine months after SAMHSA itself called the strips life-saving.

Figures span federal fiscal and calendar years from 2021 through 2026 and are cited to their original reporting period; the JAMA Network Open mortality projections are model estimates, not observed outcomes.